Address: Suite 401, Level 4, 7 Oaks Ave
Dee Why NSW 2099
Tel: 1300 138 805
Web: http://www.pharmacor.com.au/
Pharmacor’s vision is to become the new force in generic medicines by adding real value for pharmacists. In fact, pharmacy is at the very core of everything Pharmacor does. From the Pharmacy Equity Program (PEP) to offering market level discounts on all products and to the creation of a nationally recognised consumer generic brand.
As a subsidiary of PharmaCare Laboratories, Pharmacor will benefit from the synergies of its parent company’s infrastructure, allowing Pharmacor to focus on innovative and differentiated sales and marketing.
Pharmacor have partnered with leading global generic suppliers to build a broad spectrum of ethical and OTC generic products, catering for 85% of pharmacy generic purchases by mid 2008.
Generics
Wei-Hong Tseng, founder and chairman of PharmaCore Biotech, introduces the specialized CDMO and its unique capacities to produce high value-added products. As a leading service provider in Taiwan, Tseng goes…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
“Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008.…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
Senior Partner Dr Sree Haran has also participated in this interview. TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would…
The company underwent some landmark changes under your leadership, changing the balance between different pillars of the business – retail, wholesale product delivery, marketing programs. Would you begin by outlining…
After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and…
Can you start by commenting on the state of diabetes in Australia at present? According to 2011 statistics nearly one million Australians have diabetes and about half of those are…
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Would you please introduce The Pharmacy Guild to our readers, giving an insight in its function and its membership? We are the premium body representing community pharmacies in Australia, about…
Earlier this year the company set a crucial step in its internationalization strategy with the acquisition of Ascent. Would you outline the significance of the acquisition within Watson’s global expansion…
We last met you in 2008 as Chair of the Pharmaceuticals Industry Council (PIC), which set itself the goal of doubling the levels of exports, R&D investment, manufacturing, value-added activities,…
Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike…
See our Cookie Privacy Policy Here
